Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Mean Platelet Volume can Predict Cerebrovascular Events in Patients with Sickle Cell Anemia.

Celik T, Unal S, Ekinci O, Ozer C, Ilhan G, Oktay G, Arica V.

Pak J Med Sci. 2015 Jan-Feb;31(1):203-8. doi: 10.12669/pjms.311.4104.

2.

Clinical and Laboratory Predictors of Frequency of Painful Crises among Sickle Cell Anaemia Patients in Nigeria.

Ugwu AO, Ibegbulam OG, Nwagha TU, Madu AJ, Ocheni S, Okpala I.

J Clin Diagn Res. 2017 Jun;11(6):EC22-EC25. doi: 10.7860/JCDR/2017/26446.10042. Epub 2017 Jun 1.

3.

Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.

Lamarre Y, Romana M, Waltz X, Lalanne-Mistrih ML, Tressières B, Divialle-Doumdo L, Hardy-Dessources MD, Vent-Schmidt J, Petras M, Broquere C, Maillard F, Tarer V, Etienne-Julan M, Connes P.

Haematologica. 2012 Nov;97(11):1641-7. doi: 10.3324/haematol.2012.066670. Epub 2012 Jun 11.

4.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.

N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.

5.
6.

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

van Zuuren EJ, Fedorowicz Z.

Cochrane Database Syst Rev. 2015 Dec 18;(12):CD010155. doi: 10.1002/14651858.CD010155.pub3. Review.

PMID:
26684281
7.

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

van Zuuren EJ, Fedorowicz Z.

Cochrane Database Syst Rev. 2013 Jun 12;(6):CD010155. doi: 10.1002/14651858.CD010155.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(12):CD010155.

PMID:
23760785
9.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

10.

Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study.

Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, Seamon C, Peters-Lawrence M, Conrey A, Hall MK, Kato GJ, Taylor JG 6th.

PLoS One. 2013 Nov 5;8(11):e79923. doi: 10.1371/journal.pone.0079923. eCollection 2013.

11.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
12.

Significance of platelet activation in sickle cell anaemia.

Ibanga IA.

Niger J Med. 2006 Apr-Jun;15(2):148-50.

PMID:
16805172
13.
14.

Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia.

Nebor D, Bowers A, Connes P, Hardy-Dessources MD, Knight-Madden J, Cumming V, Reid M, Romana M.

PLoS One. 2014 Jan 24;9(1):e87243. doi: 10.1371/journal.pone.0087243. eCollection 2014.

15.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.

N Engl J Med. 1995 May 18;332(20):1317-22.

16.

Prevalence of hypoxemia among children with sickle cell anemia during steady state and crises: a cross-sectional study.

Chinawa JM, Ubesie AC, Chukwu BF, Ikefuna AN, Emodi IJ.

Niger J Clin Pract. 2013 Jan-Mar;16(1):91-5. doi: 10.4103/1119-3077.106774.

17.

Clinical analysis of mortality in hospitalized Zambian children with sickle cell anaemia.

Athale UH, Chintu C.

East Afr Med J. 1994 Jun;71(6):388-91.

PMID:
7835262
18.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
19.

Myocardial ischaemia in sickle cell anaemia: evaluation using a new scoring system.

Bode-Thomas F, Hyacinth HI, Ogunkunle O, Omotoso A.

Ann Trop Paediatr. 2011;31(1):67-74. doi: 10.1179/1465328110Y.0000000006.

20.

Human platelet alloantigens (HPA) 1, HPA2, HPA3, HPA4, and HPA5 polymorphisms in sickle cell anemia patients with vaso-occlusive crisis.

Al-Subaie AM, Fawaz NA, Mahdi N, Al-Absi IK, Al-Ola K, Ameen G, Almawi WY.

Eur J Haematol. 2009 Dec 1;83(6):579-85. doi: 10.1111/j.1600-0609.2009.01339.x. Epub 2009 Aug 21.

PMID:
19702628

Supplemental Content

Support Center